In type 2 diabetes, ‘something brain-friendly’ about GLP-1 receptor agonists

PHILADELPHIA — Diabetes independently increases risk for cognitive decline, yet data from several large trials suggest GLP-1 receptor agonists hold significant promise to mitigate risk for dementia-related events, according to a speaker.
“In addition to age and other risk factors, diabetes is a risk factor for cognitive decline, as is the degree of hyperglycemia,” Hertzel C. Gerstein, MD, MSc, FRCPC, professor and population health institute chair in diabetes research at McMaster University and Hamilton Health Sciences in Ontario, Canada, told Healio before speaking at the

PHILADELPHIA — Diabetes independently increases risk for cognitive decline, yet data from several large trials suggest GLP-1 receptor agonists hold significant promise to mitigate risk for dementia-related events, according to a speaker.
“In addition to age and other risk factors, diabetes is a risk factor for cognitive decline, as is the degree of hyperglycemia,” Hertzel C. Gerstein, MD, MSc, FRCPC, professor and population health institute chair in diabetes research at McMaster University and Hamilton Health Sciences in Ontario, Canada, told Healio before speaking at the